Rail Engineer.
Progress made with current and emerging biomarkers for prognosis assessment and therapeutic targeting has been summarized. Results: There has been a significant increase in research on potential biomarkers of endometrial cancer, and beneficial targeted therapies have been identified. Conclusions: Clinical trials are leading the charge for substantial gains toward personalized treatment of aggressive endometrial carcinoma subtypes. Upon completion of this activity you will be able to: • describe the most common etiologic factors for endometrial carcinoma and correlate them with its different types. • recognize the aggressive variants of endometrial carcinoma and describe their histopathologic features.